Effects of sumatriptan and eletriptan on diseased epicardial coronary arteries

European Journal of Clinical Pharmacology

Volumn 61, Issue 10, 2005, Pages 733-742

  Newman, Christopher M H ^a   Starkey, Ian ^b   Buller, Nigel ^c   Seabra Gomes, Ricardo ^d   Kirby, Simon ^e   Hettiarachchi, Jayasena ^f   Cumberland, David ^g   Hillis, William S ^h  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

^c QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^d HOSPITAL DE SANTA CRUZ   (Portugal)

^e PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^f PFIZER INC   (United States)

^g NORTHERN GENERAL HOSPITAL   (United Kingdom)

^h WESTERN INFIRMARY   (United Kingdom)

Author keywords

Coronary artery disease; Eletriptan; Sumatriptan; Triptan

Indexed keywords

ELETRIPTAN; GLYCERYL TRINITRATE; PLACEBO; SUMATRIPTAN;

ADULT; AGED; ARTERIOGRAPHY; ARTERY DIAMETER; ARTERY OCCLUSION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY THROMBOSIS; CORRELATION ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; ELECTROCARDIOGRAPHY; FEMALE; HEART MUSCLE ISCHEMIA; HEMODYNAMIC MONITORING; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; THORAX PAIN; TRANSLUMINAL CORONARY ANGIOPLASTY; VASOCONSTRICTION;

ADULT; AGED; ANGIOGRAPHY; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERIOSCLEROSIS; CORONARY VESSELS; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PYRROLIDINES; SUMATRIPTAN; TRYPTAMINES; VASOCONSTRICTOR AGENTS; VASODILATION;

EID: 27944470092     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-005-0988-4     Document Type: Article

References (36)

1. Goadsby PJ (2000) The pharmacology of headache. Prog Neurobiol 62:509-525
2. Goadsby PJ, Lipton RB, Ferrari MD (2002) Migraine - current understanding and treatment. N Engl J Med 346:257-270
3. Fox AW (2000) Comparative tolerability of oral 5-HT1B/1D agonists. Headache 40:521-527
4. Hillis WS, MacIntyre PD (1993) Sumatriptan and chest pain. Lancet 341:1564-1565
5. Ottervanger JP, van Witsen TB, Valkenburg HA, Grobbee DE, Stricker BH (1994) Adverse reactions attributed to sumatriptan. A postmarketing study in general practice. Eur J Clin Pharmacol 47:305-309
6. Visser WH, Jaspers NM, de Vriend RH, Ferrari MD (1996) Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients. Cephalalgia 16:554-559
7. Ottervanger JP, Valkenburg HA, Grobbee DE, Stricker BH (1997) Characteristics and determinants of sumatriptan-associated chest pain. Arch Neurol 54:1387-1392
8. MacIntyre PD, Bhargava B, Hogg KJ, Gemmill JD, Hillis WS (1992) The effect of i.v. sumatriptan, a selective 5-HT 1-receptor agonist on central haemodynamics and the coronary circulation. Br J Clin Pharmacol 34:541-546
9. MacIntyre PD, Bhargava B, Hogg KJ, Gemmill JD, Hillis WS (1993) Effect of subcutaneous sumatriptan, a selective 5HT1 agonist, on the systemic, pulmonary, and coronary circulation. Circulation 87:401-405
10. Hood S, Birnie D, Hillis S (1997) The haemodynamic effects of subcutaneous sumatriptan, a 5HT1-receptor agonist. Br J Clin Pharmacol 43:327-328
11. Goldstein J, Massey K, Kirby S et al (2004) Effect of high-dose intravenous eletriptan on coronary artery diameter. Cephalalgia 24:515-521
12. Hall GC, Brown MM, Mo J, MacRae KD (2004) Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice. Neurology 62:563-568
13. Stricker BH, Ottervanger JP (1993) Heart infarct following administration of sumatriptan (Imigran). Ned Tijdschr Geneeskd 137:141
14. Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH (1993) Transmural myocardial infarction with sumatriptan. Lancet 341:861-862
15. Mueller L, Gallagher RM, Ciervo CA (1996) Vasospasm-induced myocardial infarction with sumatriptan. Headache 36:329-331
16. Ottervanger JP, Wilson JH, Stricker BH (1997) Drug-induced chest pain and myocardial infarction. Reports to a national centre and review of the literature. Eur J Clin Pharmacol 53:105-110
17. Widlansky ME, Gokce N, Keaney JF Jr, Vita JA (2003) The clinical implications of endothelial dysfunction. J Am Coll Cardiol 42:1149-1160
18. Connor HE, Feniuk W, Humphrey PP (1989) 5-Hydroxytryptamine contracts human coronary arteries predominantly via 5-HT2 receptor activation. Eur J Pharmacol 161:91-94
19. Bax WA, Heuven-Nolsen D, Bos E, Simoons ML, Saxena PR (1992) 5-Hydroxytryptamine-induced contractions of the human isolated saphenous vein: involvement of 5-HT2 and 5-HT1D-like receptors, and a comparison with grafted veins. Naunyn Schmiedebergs Arch Pharmacol 345:500-508
20. Bax WA, Renzenbrink GJ, Van Heuven-Nolsen D, Thijssen EJ, Bos E, Saxena PR (1993) 5-HT receptors mediating contractions of the isolated human coronary artery. Eur J Pharmacol 239:203-210
21. Nilsson T, Longmore J, Shaw D et al (1999) Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. Eur J Pharmacol 372:49-56
22. Kaumann AJ, Frenken M, Posival H, Brown AM (1994) Variable participation of 5-HT1-like receptors and 5-HT2 receptors in serotonin-induced contraction of human isolated coronary arteries. 5-HT1-like receptors resemble cloned 5-HT1D beta receptors. Circulation 90:1141-1153
23. Ishida T, Kawashima S, Hirata Ki et al (2001) Serotonin-induced hypercontraction through 5-hydroxytryptamine 1B receptors in atherosclerotic rabbit coronary arteries. Circulation 103:1289-1295
24. Longmore J, Maguire JJ, MacLeod A, Street L, Schofield WN, Hill RG (2000) Comparison of the vasoconstrictor effects of the selective 5-HT1D-receptor agonist L-775,606 with the mixed 5-HT1B/1D-receptor agonist sumatriptan and 5-HT in human isolated coronary artery. Br J Clin Pharmacol 49:126-131
25. Carel I, Ghaleh B, Edouard A et al (2001) Comparative effects of frovatriptan and sumatriptan on coronary and internal carotid vascular haemodynamics in conscious dogs. Br J Pharmacol 132:1071-1083
26. Hamel E, Fan E, Linville D, Ting V, Villemure JG, Chia LS (1993) Expression of mRNA for the serotonin 5-hydroxytryptamine1D beta receptor subtype in human and bovine cerebral arteries. Mol Pharmacol 44:242-246
27. Sgard F, Faure C, Graham D (1996) Evidence for 5-HT1D beta but not 5-HT1D alpha receptor subtype expression in canine large coronary arteries and saphenous vein. Cardiovasc Res 31:793-799
28. Bouchelet I, Case B, Olivier A, Hamel E (2000) No contractile effect for 5-HT1D and 5-HT1F receptor agonists in human and bovine cerebral arteries: similarity with human coronary artery. Br J Pharmacol 129:501-508
29. Muir DF, McCann GP, Swan L, Clark AL, Hillis WS (1999) Hemodynamic and coronary effects of intravenous eletriptan, a 5HT1B/1D-receptor agonist. Clin Pharmacol Ther 66:85-90
30. Hood S, Birnie D, Swan L et al (1999) Effects of subcutaneous naratriptan on systemic and pulmonary haemodynamics and coronary artery diameter in humans. J Cardiovasc Pharmacol 34:89-94
31. Maassen-van den Brink A, van den Broek RW, de Vries R, Bogers AJ, Avezaat CJ, Saxena PR (2000) Craniovascular selectivity of eletriptan and sumatriptan in human isolated blood vessels. Neurology 55:1524-1530
32. Relpax product website. Available at http://www.pfizer.com/download/ uspi_relpax.pdf. Accessed April 2005.
33. Imitrex product website. Available at http://us.gsk.com/products/assets/ us_imitrex_tablets.pdf. Accessed April 2005.
34. Elkind AH, Satin LZ, Nil A, Keywood C (2004) Frovatriptan use in migraineurs with or at high risk of coronary artery disease. Headache 44:403-410
35. Gnecchi-Ruscone T, Bernard X, Pierre P et al (2000) Effect of naratriptan on myocardial blood flow and coronary vasodilator reserve in migraineurs. Neurology 55:95-99
36. Dahlof CG, Mathew N (1998) Cardiovascular safety of 5HT1B/1D agonists - is there a cause for concern? Cephalalgia 18:539-545